Pro Medicus (ASX: PME) scores A$44m U.S. imaging deal as Visage 7 cloud wins more converts

Pro Medicus Limited (ASX: PME) has signed a five-year, A$44 million cloud-based enterprise imaging contract with Advanced Radiology Management, deepening its presence in the North American private radiology sector. The deal, announced on November 17, 2025, confirms the continued momentum of the Australian health informatics firm’s cloud-first strategy and the accelerating adoption of its Visage 7 platform in high-throughput diagnostic environments.

The agreement will see Pro Medicus Limited’s wholly owned U.S. subsidiary, Visage Imaging, Inc., roll out the Visage 7 Enterprise Imaging Platform across the Advanced Radiology Management network. The deployment will include the company’s flagship Visage 7 Viewer and will be delivered entirely via the cloud. Planning for the implementation has already begun, with go-live targeted for late in the second quarter of the 2026 calendar year.

This contract is structured on a transaction-based licensing model, allowing Advanced Radiology Management to scale capacity in line with case volume and eliminate major upfront infrastructure costs. The operational flexibility and improved time-to-value of such cloud-native deployments have become key selling points for private radiology groups looking to modernize diagnostic infrastructure amid mounting volume and workforce challenges.

Chief Executive Officer Dr Sam Hupert stated that the addition of Advanced Radiology Management underscores the growing industry consensus around cloud-based enterprise imaging platforms. He highlighted the increasing need among radiology providers to improve productivity and reduce burnout at a time when the supply of qualified radiologists is not keeping pace with imaging demand. The North American radiology market, he noted, has become one of the most competitive yet opportunity-rich arenas for scalable, cloud-native PACS solutions.

Advanced Radiology Management is a prominent private radiology reading group known for its focus on high-quality remote diagnostics and collaborative interpretation workflows. Its partnership with Pro Medicus Limited reflects an industry-wide shift toward unified, cloud-native platforms that consolidate imaging across multiple modalities, facilities, and patient pathways.

What does the Visage 7 deployment signal about cloud PACS adoption in private radiology?

The Visage 7 platform has increasingly emerged as a preferred replacement for legacy PACS systems in both academic and private settings. Built around ultrafast rendering capabilities, native cloud deployment, and a seamless enterprise viewer interface, Visage 7 enables high-volume imaging providers to streamline interpretation workflows and scale access across radiologist teams.

In private radiology, where practices often operate across distributed geographies and support hospital and outpatient partners in real-time, the ability to consolidate image access and interpretation into a single, high-performance platform becomes a core advantage. Visage 7 allows radiologists to work with complex multimodality datasets without latency issues, while also supporting AI integration and advanced visualization tools.

What differentiates Pro Medicus Limited’s approach is not just the platform itself, but the go-to-market model. The transaction-based licensing structure aligns software costs with imaging volume, appealing to private groups that want predictability and scalability. Rather than invest upfront in large server infrastructure or perpetual licenses, clients like Advanced Radiology Management can ramp usage dynamically while benefiting from ongoing platform updates and optimization.

Dr Sam Hupert explained that the pressure on radiologists to interpret more imaging studies in shorter timeframes is contributing to burnout across the profession. With Visage 7, he said, radiologists typically see efficiency gains within hours of go-live, helping alleviate some of the workload pressures and clinical fatigue. This immediate improvement in speed and interpretive workflow is becoming a strong draw for practices seeking not just modernization, but clinician relief and retention.

How this U.S. deal strengthens Pro Medicus Limited’s strategic market position

The contract with Advanced Radiology Management follows a string of high-profile North American client wins and expands Pro Medicus Limited’s footprint in one of the world’s most mature and technologically advanced healthcare IT markets. The United States remains a cornerstone growth market for the Australian firm, which has steadily pivoted its portfolio toward cloud-native enterprise imaging systems designed to replace multi-vendor, fragmented legacy infrastructure.

From a financial standpoint, multi-year contracts like this one contribute to a growing base of recurring revenue. Analysts tracking the company note that such deals tend to be high-margin, particularly given the software-as-a-service structure that minimizes hardware and support costs. Pro Medicus Limited has consistently reported strong operating leverage as more clients transition to cloud-based usage models that scale with volume and require minimal onsite servicing.

The strategic importance of this deal also lies in its signal to the broader market. Private practice groups, often viewed as more price-sensitive or slower to adopt new enterprise IT models, are now clearly embracing transaction-based cloud imaging solutions. This implies that cloud PACS is no longer confined to large academic centers or public health systems. The private radiology segment is evolving rapidly, and vendors that offer proven efficiency gains are emerging as preferred partners.

In recent investor briefings, Pro Medicus Limited executives have pointed to the increasing contribution of private sector deals to the company’s overall pipeline. With Advanced Radiology Management now onboard, Visage 7 continues to build critical mass in a competitive and high-value segment of the market.

How does the University Hospital Heidelberg deal validate Visage 7’s global flexibility?

While the North American focus remains central to the company’s growth narrative, Pro Medicus Limited also continues to expand its reach across Europe. In October 2025, the company announced a five-year, A$10 million contract with University Hospital Heidelberg and the German Cancer Research Center, along with associated hospitals including Thoraxklinik Heidelberg and KKH Bergstrasse.

That deployment involves replacing three legacy PACS systems and consolidating diagnostic imaging workflows under a single Visage 7 platform. Importantly, the Heidelberg agreement highlights Visage 7’s appeal beyond clinical interpretation and into translational research. The platform’s performance and scalability are seen as instrumental in bridging clinical care with imaging-rich research, especially in academic settings.

Oliver Reinhard, Chief Information Officer at Heidelberg University Hospital, noted that Visage 7 provides a future-ready diagnostic environment while also supporting large-scale imaging research. The ability to integrate imaging datasets into clinical trials and scientific workflows has become increasingly important for institutions where research and care delivery are deeply intertwined.

This dual clinical-research positioning enhances Visage 7’s value proposition globally, allowing Pro Medicus Limited to address a wide range of clients with different needs, from remote-reading private groups in the U.S. to advanced research hospitals in Europe. The Heidelberg deal also validates the product’s ability to scale across multiple institutions, language environments, and regional compliance frameworks.

What lies ahead for Pro Medicus Limited as it builds on this momentum?

Investor interest in Pro Medicus Limited remains high, driven by its consistent financial performance, global contract wins, and the growing acceptance of its cloud-first strategy. Shares of Pro Medicus Limited [ASX: PME] have historically rallied on the back of large deal announcements, and the Advanced Radiology Management contract fits the mold of a high-confidence, revenue-accretive engagement.

Brokerage analysts have maintained positive sentiment on the stock, citing strong gross margins, high customer retention, and a pipeline that continues to produce both geographic and sectoral diversification. With offices in Melbourne, Berlin, and San Diego, the company is now positioned to compete across multiple healthcare IT markets simultaneously.

The focus over the next two quarters will likely shift toward execution. Investors and analysts will be watching the pace of implementation at Advanced Radiology Management, the volume growth associated with the transaction-based model, and any further deal announcements as the 2026 calendar year unfolds.

Pro Medicus Limited’s ability to deliver immediate clinical value while supporting long-term IT transformation remains its core advantage. As healthcare systems around the world continue to prioritize efficiency, scalability, and interoperability, the Visage 7 platform appears well positioned to meet those demands across both private and public sector clients.

What are the key takeaways from the Pro Medicus and Advanced Radiology Management deal?

• Pro Medicus Limited [ASX: PME] has signed a five-year, A$44 million contract with Advanced Radiology Management, a U.S.-based private radiology group.
• The deal will deploy the cloud-based Visage 7 Enterprise Imaging Platform, including the Visage 7 Viewer, across the client’s network with go-live targeted for late Q2 2026.
• The agreement is structured on a transaction-based model that scales with diagnostic imaging volume, offering operational and financial flexibility.
• This win reinforces Pro Medicus Limited’s CloudPACS strategy and its growing penetration in the North American private radiology market.
• CEO Dr Sam Hupert cited radiologist shortages and rising imaging volumes as key factors driving adoption of cloud-native solutions like Visage 7.
• The deal follows an October 2025 contract with University Hospital Heidelberg in Germany, further validating Visage 7’s global scalability and research-grade capabilities.
• Investor sentiment remains bullish, with analysts watching closely for deployment pace, volume ramp-up, and additional contract wins in 2026.
• The Visage 7 platform continues to gain traction as a next-generation alternative to legacy PACS, especially among high-throughput, multi-site radiology providers.